Showing results (81-90 of 143) with videos related to

Sort By:
Pageof 15
Leukemia & Lymphoma|August 12, 2023
Use of tamibarotene, a potent and selective RARα agonist, in combination with azacitidine in patients with relapsed and refractory AML with RARA gene overexpressionEytan M Stein, Stephane de Botton, Thomas Cluzeau, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 19, 2010
Addition of lomustine to idarubicin and cytarabine improves the outcome of elderly patients with de novo acute myeloid leukemia: a report from the GOELAMSArnaud Pigneux, Jean-Luc Harousseau, Francis Witz, et al.
Cancers|March 29, 2020
Outcome of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia Before Second-Generation FLT3 Tyrosine Kinase Inhibitors: A Toulouse-Bordeaux DATAML Registry StudySarah Bertoli, Pierre-Yves Dumas, Emilie Bérard, et al.
Blood|May 31, 2011
Dismal prognostic value of monosomal karyotype in elderly patients with acute myeloid leukemia: a GOELAMS study of 186 patients with unfavorable cytogenetic abnormalitiesAurore Perrot, Isabelle Luquet, Arnaud Pigneux, et al.
European Journal of Haematology|January 26, 2017
Impact of body-surface area on patients' outcome in younger adults with acute myeloid leukemiaXavier Cahu, Martin Carré, Christian Recher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2017
Randomized Phase II Study of Clofarabine-Based Consolidation for Younger Adults With Acute Myeloid Leukemia in First RemissionXavier Thomas, Stéphane de Botton, Sylvie Chevret, et al.
Haematologica|August 27, 2013
Prognostic impact of day 15 blast clearance in risk-adapted remission induction chemotherapy for younger patients with acute myeloid leukemia: long-term results of the multicenter prospective LAM-2001 trial by the GOELAMS study groupSarah Bertoli, Pierre Bories, Marie C Béné, et al.
Blood Advances|August 14, 2020
Delivering HDAC over 3 or 5 days as consolidation in AML impacts health care resource consumption but not outcomePierre-Yves Dumas, Sarah Bertoli, Emilie Bérard, et al.
Leukemia|February 5, 2021
Allogeneic hematopoietic stem cell transplantation for adult patients with t(4;11)(q21;q23) KMT2A/AFF1 B-cell precursor acute lymphoblastic leukemia in first complete remission: impact of pretransplant measurable residual disease (MRD) status. An analysis from the Acute Leukemia Working Party of the EBMTJordi Esteve, Sebastian Giebel, Myriam Labopin, et al.
Leukemia|July 17, 2024
Molecular relapse after first-line intensive therapy in patients with CBF or NPM1-mutated acute myeloid leukemia - a FILO studyCorentin Orvain, Sarah Bertoli, Pierre Peterlin, et al.
Pageof 15